|
1
|
Medina MA, Oza G, Sharma A, Arriaga LG,
Hernandez Hernandez JM, Rotello VM and Ramirez JT: Triple-negative
breast cancer: A review of conventional and advanced therapeutic
strategies. Int J Environ Res Public Health. 17:20782020.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
da Silva JL, Cardoso Nunes NC, Izetti P,
de Mesquita GG and de Melo AC: Triple negative breast cancer: A
thorough review of biomarkers. Crit Rev Oncol Hematol.
145:1028552020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pandy JGP, Balolong-Garcia JC,
Cruz-Ordinario MVB and Que FVF: Triple negative breast cancer and
platinum-based systemic treatment: A meta-analysis and systematic
review. BMC Cancer. 19:10652019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
De Laurentiis M, Cianniello D, Caputo R,
Stanzione B, Arpino G, Cinieri S, Lorusso V and De Placido S:
Treatment of triple negative breast cancer (TNBC): Current options
and future perspectives. Cancer Treat Rev. 36 (Suppl 3):S80–S86.
2010. View Article : Google Scholar
|
|
5
|
Wang KC and Chang HY: Molecular mechanisms
of long noncoding RNAs. Mol Cell. 43:904–914. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mercer TR, Dinger ME and Mattick JS: Long
non-coding RNAs: Insights into functions. Nat Rev Genet.
10:155–159. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fabian MR, Sonenberg N and Filipowicz W:
Regulation of mRNA translation and stability by microRNAs. Annu Rev
Biochem. 79:351–379. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mohr AM and Mott JL: Overview of microRNA
biology. Semin Liver Dis. 35:3–11. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lu TX and Rothenberg ME: MicroRNA. J
Allergy Clin Immunol. 141:1202–1207. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rodriguez Bautista R, Ortega Gómez A,
Hidalgo Miranda A, Zentella Dehesa A, Villarreal-Garza C,
Ávila-Moreno F and Arrieta O: Long non-coding RNAs: Implications in
targeted diagnoses, prognosis, and improved therapeutic strategies
in human non- and triple-negative breast cancer. Clin Epigenetics.
10:882018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang Q, Gao S, Li H, Lv M and Lu C: Long
noncoding RNAs (lncRNAs) in triple negative breast cancer. J Cell
Physiol. 232:3226–3233. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kong X, Liu W and Kong Y: Roles and
expression profiles of long non-coding RNAs in triple-negative
breast cancers. J Cell Mol Med. 22:390–394. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Piasecka D, Braun M, Kordek R, Sadej R and
Romanska H: MicroRNAs in regulation of triple-negative breast
cancer progression. J Cancer Res Clin Oncol. 144:1401–1411. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Naorem LD, Prakash VS, Muthaiyan M and
Venkatesan A: Comprehensive analysis of dysregulated lncRNAs and
their competing endogenous RNA network in triple-negative breast
cancer. Int J Biol Macromol. 145:429–436. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xu ST, Xu JH, Zheng ZR, Zhao QQ, Zeng XS,
Cheng SX, Liang YH and Hu QF: Long non-coding RNA ANRIL promotes
carcinogenesis via sponging miR-199a in triple-negative breast
cancer. Biomed Pharmacother. 96:14–21. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fan H, Yuan J and Li X, Ma Y, Wang X, Xu B
and Li X: LncRNA LINC00173 enhances triple-negative breast cancer
progression by suppressing miR-490-3p expression. Biomed
Pharmacother. 125:1099872020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mehra R, Udager AM, Ahearn TU, Cao X, Feng
FY, Loda M, Petimar JS, Kantoff P, Mucci LA and Chinnaiyan AM:
Overexpression of the Long Non-coding RNA SChLAP1 independently
predicts lethal prostate cancer. Eur Urol. 70:549–552. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Prensner JR, Iyer MK, Sahu A, Asangani IA,
Cao Q, Patel L, Vergara IA, Davicioni E, Erho N, Ghadessi M, et al:
The long noncoding RNA SChLAP1 promotes aggressive prostate cancer
and antagonizes the SWI/SNF complex. Nat Genet. 45:1392–1398. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li Y, Luo H, Xiao N, Duan J, Wang Z and
Wang S: Long noncoding RNA SChLAP1 accelerates the proliferation
and metastasis of prostate cancer via targeting miR-198 and
promoting the MAPK1 pathway. Oncol Res. 26:131–143. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang J, Shi Z, Nan Y and Li M: Inhibiting
malignant phenotypes of the bladder cancer cells by silencing long
noncoding RNA SChLAP1. Int Urol Nephrol. 48:711–716. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dobin A, Davis CA, Schlesinger F, Drenkow
J, Zaleski C, Jha S, Batut P, Chaisson M and Gingeras TR: STAR:
Ultrafast universal RNA-seq aligner. Bioinformatics. 29:15–21.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liao Y, Smyth GK and Shi W: featureCounts:
An efficient general purpose program for assigning sequence reads
to genomic features. Bioinformatics. 30:923–930. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chen Y and Wang X: miRDB: An online
database for prediction of functional microRNA targets. Nucleic
Acids Res. 48:D127–D131. 2020. View Article : Google Scholar
|
|
26
|
Ji J, Xu R, Ding K, Bao G, Zhang X, Huang
B, Wang X, Martinez A, Wang X, Li G, et al: Long Noncoding RNA
SChLAP1 forms a growth-promoting complex with HNRNPL in human
glioblastoma through stabilization of ACTN4 and activation of NF-κB
signaling. Clin Cancer Res. 25:6868–6881. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Thomson DW and Dinger ME: Endogenous
microRNA sponges: Evidence and controversy. Nat Rev Genet.
17:272–283. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chan JJ and Tay Y: Noncoding RNA: RNA
regulatory networks in cancer. Int J Mol Sci. 19:3102018.
View Article : Google Scholar
|
|
29
|
Tay Y, Rinn J and Pandolfi PP: The
multilayered complexity of ceRNA crosstalk and competition. Nature.
505:344–352. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu H, Chen X, Lin T, Chen X, Yan J and
Jiang S: MicroRNA-524-5p suppresses the progression of papillary
thyroid carcinoma cells via targeting on FOXE1 and ITGA3 in cell
autophagy and cycling pathways. J Cell Physiol. 234:18382–18391.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liu GH, Liu YH, Yang Z, Zhu AL and Zhao
CL: MicroRNA-524-5p suppresses the growth and invasive abilities of
gastric cancer cells. Oncol Lett. 11:1926–1932. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhu CY, Meng FQ and Liu J: MicroRNA-524-5p
suppresses cell proliferation and promotes cell apoptosis in
gastric cancer by regulating CASP3. Eur Rev Med Pharmacol Sci.
23:7968–7977. 2019.PubMed/NCBI
|
|
33
|
Zhen W, Qiu D, Zhiyong C, Xin W, Mengyao
J, Dimin Z, Chonghui H, Haijun W and Yonghong Z: MicroRNA-524-5p
Functions as a tumor suppressor in a human pituitary tumor-derived
cell line. Horm Metab Res. 49:550–557. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhao K, Wang Q, Wang Y, Huang K, Yang C,
Li Y, Yi K and Kang C: EGFR/c-myc axis regulates TGFβ/Hippo/Notch
pathway via epigenetic silencing miR-524 in gliomas. Cancer Lett.
406:12–21. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhang S, Mo Q and Wang X: Oncological role
of HMGA2 (Review). Int J Oncol. 55:775–788. 2019.PubMed/NCBI
|
|
36
|
De Martino M, Fusco A and Esposito F: HMGA
and Cancer: A review on patent literatures. Recent Pat Anticancer
Drug Discov. 14:258–267. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Huang YM, Cheng CH, Pan SL, Yang PM, Lin
DY and Lee KH: Gene expression signature-based approach identifies
antifungal drug ciclopirox as a novel inhibitor of HMGA2 in
colorectal cancer. Biomolecules. 9:6882019. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kang NN, Ge SL, Zhang RQ, Huang YL, Liu SD
and Wu KM: MiR-490-3p inhibited the proliferation and metastasis of
esophageal squamous cell carcinoma by targeting HMGA2. Eur Rev Med
Pharmacol Sci. 22:8298–8305. 2018.PubMed/NCBI
|
|
39
|
Xing F, Song Z and He Y: MiR-219-5p
inhibits growth and metastasis of ovarian cancer cells by targeting
HMGA2. Biol Res. 51:502018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Sun J, Qiao Y, Song T and Wang H: MiR495
suppresses cell proliferation by directly targeting HMGA2 in lung
cancer. Mol Med Rep. 19:1463–1470. 2019.PubMed/NCBI
|
|
41
|
Wang MJ, Zhang H, Li J and Zhao HD:
microRNA-98 inhibits the proliferation, invasion, migration and
promotes apoptosis of breast cancer cells by binding to HMGA2.
Biosci Rep. 38:BSR201805712018. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wang J, Liang H, Ge H, Guo X, Gu D and
Yuan Y: MicroRNA3633p inhibits hepatocarcinogenesis by targeting
HMGA2 and is associated with liver cancer stage. Mol Med Rep.
19:935–942. 2019.PubMed/NCBI
|
|
43
|
Xu X, Zou H, Luo L, Wang X and Wang G:
MicroRNA-9 exerts antitumor effects on hepatocellular carcinoma
progression by targeting HMGA2. FEBS Open Bio. 9:1784–1797. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Xi X, Teng M, Zhang L, Xia L, Chen J and
Cui Z: MicroRNA-204-3p represses colon cancer cells proliferation,
migration, and invasion by targeting HMGA2. J Cell Physiol.
235:1330–1338. 2020. View Article : Google Scholar : PubMed/NCBI
|
